Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹2,752 Cr
verified against source
Revenue YoY
—
reported change
EBITDA
Pending
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Piramal Pharma reported a transitional FY26 with revenue decline due to inventory destocking in a key on-patent commercial product, subdued biotech funding in H1, and intensified competition in inhalation anesthesia in non-US markets. However, excluding the destocking impact, underlying business showed modest growth. CDMO saw strong RFP and order inflow recovery in H2, with win rates improving. Consumer healthcare grew 17% in Q4 and 17% for the full year, with power brands up 24%. The company guided for early-to-mid teens revenue growth in FY27, with EBITDA growing faster, excluding the destocked product. Risks include prolonged Middle East tensions causing cost escalations, tariff uncertainties, and the lumpy nature of CDMO revenue skewing to H2.
Colored figures show movement against the previous available record.
Guidance to track
- Management expects consolidated revenue growth in the early-to-mid teens for FY27, excluding the previously destocked on-patent commercial product.
- EBITDA is expected to grow faster than revenue, supported by operating leverage from higher scale.
- Capital expenditure for FY27 is guided at $120-135 million, primarily for Lexington expansion and other growth projects.
- Net debt to EBITDA is expected to remain range-bound at about 3.6x for FY27, with long-term target of 1x.
Risks flagged
- Prolonged Middle East tensions may increase costs for sourcing, logistics, and working capital, with limited ability to pass through.
- US tariffs on Indian pharma could affect innovation-related work; management noted multiple mitigation paths but uncertainty remains.
- A ₹176 crore impairment was taken on R&D intangibles due to changed market conditions; similar write-offs may recur.
- CDMO revenue remains H2-weighted, causing quarterly volatility; this pattern is expected to persist in FY27.
Key quotes
- We're currently anticipating revenue growth in the early to mid teens with EBITDA expected to grow faster than revenue supported by operating leverage.
- We actually saw our win rate increase last year versus the prior year. And we think that's because of a couple of factors.
- We achieved a net promoter score of 60, surpassing the industry average and reflecting high levels of customer satisfaction.
Research modules